The US assisted reproductive technology (ART) market has witnessed significant growth over the past decade, driven by increasing infertility rates, technological advancements, and growing awareness about fertility treatments. ART encompasses a range of medical procedures, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), artificial insemination, and embryo cryopreservation, aimed at addressing infertility challenges among couples. Persistence Market Research reports that the market is projected to reach a valuation of US$11.3 billion by 2031, expanding at a CAGR of 17.8% between 2024 and 2031.
The historical growth of the market, from US$3.6 billion in 2024, has been largely fueled by technological innovations in reproductive medicine, increased R&D in fertility treatments, and the establishment of specialized fertility clinics. Leading ART techniques such as IVF have become mainstream, supported by sophisticated laboratory practices and higher success rates. The US remains a frontrunner in ART adoption due to robust healthcare infrastructure, extensive research initiatives, and supportive government policies that enhance treatment accessibility.
Market Statistics and Key Growth Drivers
The prevalence of infertility in the US population is a primary driver of market growth. According to recent studies, approximately 7% of women aged 15–44 experience infertility, while male infertility affects roughly 10% of men aged 16–74. Lifestyle factors such as obesity, stress, and sedentary habits contribute to this rising trend, which is further amplified by delayed parenthood. Persistence Market Research emphasizes that the growing need for fertility preservation among cancer patients and young women is also shaping market dynamics.
R&D investments are another pivotal factor. Advanced technologies such as AI-driven embryo selection, preimplantation genetic testing (PGT), and improved cryopreservation methods are enhancing the effectiveness of ART procedures. The integration of AI into fertility clinics allows for personalized treatment plans, improving success rates and patient outcomes. These advancements, combined with increasing patient awareness, are expected to sustain high growth rates over the forecast period.
Leading Segment and Geographical Insights
The IVF segment dominates the US ART market, accounting for around 80% of market share in 2023. Its high procedural success rate and continuous technological enhancements make IVF the most preferred ART technique. Fertility clinics, on the other hand, constitute nearly 70% of end-user revenue due to their specialization, cost-effectiveness, and personalized patient care services.
Geographically, North America, particularly the United States, leads the global ART market due to advanced healthcare infrastructure, high R&D expenditure, and government support for fertility treatments. Rising awareness about infertility, coupled with the presence of major fertility clinics and research institutions, reinforces the US’s dominance in this sector.
Key Highlights from the Report
• The rise in infertility cases and increased R&D activity in infertility treatment procedures primarily drive demand in the market.
• The US assisted reproductive technology market is estimated to exhibit a staggering growth rate of 9.2% over the forecast period.
• The rise in the prevalence of infertility in the US population is a major market driving element.
• Rising demand for fertility preservation services among young women and cancer patients will be a crucial market trend.
• Increased research and development activities in the fertility domain are aiding market growth.
• ART procedures such as IVF are witnessing technological advancements that improve success rates and patient outcomes.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34680
Market Segmentation:
The US ART market can be segmented by technique and end-use, offering a comprehensive understanding of demand patterns. In terms of technique, IVF dominates, followed by artificial insemination and other assisted procedures. IVF’s popularity stems from its consistent success rates, technological innovations such as time-lapse embryo monitoring, and advanced sperm selection methods. Artificial insemination is widely used for less severe infertility cases and for patients seeking cost-effective solutions, though it holds a smaller market share compared to IVF.
By end-use, fertility clinics account for the majority of the market share due to specialized services, personalized care, and high procedural efficiency. Hospitals offer ART services as well, but they generally provide less individualized care and see slower growth. The expansion of fertility clinics is fueled by the increasing prevalence of infertility, patient preference for dedicated facilities, and rising investments in specialized reproductive healthcare infrastructure.
Regional Insights
North America, particularly the United States, continues to dominate the ART market due to superior healthcare infrastructure, high awareness of infertility treatments, and a well-established network of fertility clinics. Additionally, supportive government initiatives and high per capita healthcare expenditure contribute to market growth in the region.
In contrast, emerging regions such as Asia-Pacific are witnessing steady growth due to rising awareness, increasing disposable income, and gradual improvements in healthcare infrastructure. However, adoption rates remain lower compared to the US, highlighting the potential for expansion in these regions.
Market Drivers
The US ART market growth is primarily driven by the rising prevalence of infertility among men and women. Lifestyle changes, delayed parenthood, and increased obesity rates have intensified infertility challenges. Furthermore, growing awareness about fertility preservation and advances in ART technologies, such as AI-assisted embryo selection and PGT, are fueling market demand.
Market Restraints
High costs of ART procedures remain a key restraint. IVF and related treatments require sophisticated equipment, skilled professionals, and multiple treatment cycles, which can impose significant financial burdens. Additionally, potential health risks associated with ART, including ovarian hyperstimulation syndrome (OHSS), low birth weight, and multiple pregnancies, may deter some patients from seeking treatment.
Market Opportunities
Emerging opportunities in the US ART market include growing awareness about male infertility and fertility preservation. Innovative technologies, such as time-lapse imaging for embryos, AI integration, and enhanced cryopreservation techniques, provide new avenues for market growth. Expansion of fertility clinics and increased investment in R&D for reproductive health further bolster these opportunities.
Reasons to Buy the Report
Comprehensive analysis of market trends, growth drivers, and restraints.
Detailed segmentation by technique, end-user, and geography.
Insights into emerging technologies and innovative ART procedures.
Competitive landscape analysis with key players and recent developments.
Forecast and growth projections through 2031 for informed business decisions.
Frequently Asked Questions (FAQs):
• How big is the US assisted reproductive technology market?
• Who are the key players in the global market for assisted reproductive technology?
• What is the projected growth rate of the US ART market?
• What is the market forecast for 2032?
• Which region is estimated to dominate the industry through the forecast period?
Company Insights:
The US assisted reproductive technology market features numerous leading players focused on innovation and patient-centric care. Key companies include:
• The Fertility Institutes
• Shady Grove Fertility
• Pacific Fertility Centre
• Boston IVF
• Cleveland Clinic Fertility Centre
• Reproductive Medicine Associates of New Jersey (RMANJ)
• Columbia University Fertility Centre
• Mayo Clinic Fertility Centre
• Texas Fertility Centre
• UCSF Centre for Reproductive Health
Recent Developments:
• January 2024: Ivy Fertility partnered with SMP Pharmacy Solutions to enhance patient experiences across its 13 reproductive locations.
• October 2023: Hamilton Thorne Ltd. acquired Genetics Medical Products and Genetics Services, expanding its portfolio of innovative IVF devices.
Conclusion:
The US assisted reproductive technology market is poised for remarkable growth, driven by rising infertility rates, technological advancements, and increasing awareness of fertility treatments. With IVF leading as the dominant technique and fertility clinics serving as primary end-users, the market is supported by strong infrastructure, research initiatives, and patient-centric healthcare services. Persistence Market Research highlights that ongoing innovations, such as AI-assisted embryo selection, preimplantation genetic testing, and advanced cryopreservation techniques, will continue to enhance success rates and patient outcomes.
Despite challenges such as high treatment costs and potential health risks, the market offers significant opportunities for expansion, particularly through growing awareness of male infertility and fertility preservation. Regional dominance by the United States underscores the impact of robust healthcare systems and high R&D expenditure, while emerging markets offer long-term growth potential. Overall, the US ART market represents a dynamic and rapidly evolving segment of reproductive healthcare, promising both technological progress and improved access to life-changing fertility treatments for patients nationwide.
Read Related Reports:
